Literature DB >> 28730408

Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders.

Kristen A McLaurin1, Rosemarie M Booze1, Charles F Mactutus2.   

Abstract

Understanding the progression of HIV-1-associated neurocognitive disorders (HAND) is a critical need as the prevalence of HIV-1 in older individuals (>50 years) is markedly increasing due to the great success of combination antiretroviral therapy (cART). Longitudinal experimental designs, in comparison to cross-sectional studies, provide an opportunity to establish age-related disease progression in HAND. The HIV-1 transgenic (Tg) rat, which has been promoted for investigating the effect of long-term HIV-1 viral protein exposure, was used to examine two interrelated goals. First, to establish the integrity of sensory and motor systems through the majority of the animal's functional lifespan. Strong evidence for intact sensory and motor system function through advancing age in HIV-1 Tg and control animals was observed in cross-modal prepulse inhibition (PPI) and locomotor activity. The integrity of sensory and motor system function suggested the utility of the HIV-1 Tg rat in investigating the progression of HAND. Second, to assess the progression of neurocognitive impairment, including temporal processing and long-term episodic memory, in the HIV-1 Tg rat; the factor of biological sex was integral to the experimental design. Cross-modal PPI revealed significant alterations in the development of temporal processing in HIV-1 Tg animals relative to controls; alterations which were more pronounced in female HIV-1 Tg rats relative to male HIV-1 Tg rats. Locomotor activity revealed deficits in intrasession habituation, suggestive of a disruption in long-term episodic memory, in HIV-1 Tg animals. Understanding the progression of HAND heralds an opportunity for the development of an advantageous model of progressive neurocognitive deficits in HIV-1 and establishes fundamental groundwork for the development of neurorestorative treatments.

Entities:  

Keywords:  Episodic memory; HIV-1 transgenic rat; HIV-1-associated neurocognitive disorders; Temporal processing

Mesh:

Year:  2017        PMID: 28730408      PMCID: PMC5775943          DOI: 10.1007/s13365-017-0544-x

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  74 in total

1.  How can we learn about developmental processes from cross-sectional studies, or can we?

Authors:  H C Kraemer; J A Yesavage; J L Taylor; D Kupfer
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

2.  Advanced statistics: statistical methods for analyzing cluster and cluster-randomized data.

Authors:  Robert L Wears
Journal:  Acad Emerg Med       Date:  2002-04       Impact factor: 3.451

3.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

4.  Reflex modification as a test for sensory function.

Authors:  J R Wecker; J R Ison; J A Foss
Journal:  Neurobehav Toxicol Teratol       Date:  1985 Nov-Dec

5.  Using intracranial electrical stimulation to study the timing of prepulse inhibition of the startle reflex.

Authors:  L Li; J S Yeomans
Journal:  Brain Res Brain Res Protoc       Date:  2000-02

6.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

Authors:  W Reid; M Sadowska; F Denaro; S Rao; J Foulke; N Hayes; O Jones; D Doodnauth; H Davis; A Sill; P O'Driscoll; D Huso; T Fouts; G Lewis; M Hill; R Kamin-Lewis; C Wei; P Ray; R C Gallo; M Reitz; J Bryant
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.

Authors:  Landhing M Moran; Sylvia Fitting; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2014-10-05       Impact factor: 2.457

8.  The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART.

Authors:  Jinsong Peng; Michael Vigorito; Xiangqian Liu; Dunjing Zhou; Xiongwen Wu; Sulie L Chang
Journal:  J Neuroimmunol       Date:  2009-11-13       Impact factor: 3.478

9.  Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands.

Authors:  J McGaughy; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

10.  Neurobehavioral Abnormalities in the HIV-1 Transgenic Rat Do Not Correspond to Neuronal Hypometabolism on 18F-FDG-PET.

Authors:  William C Reid; Rafael Casas; Georgios Z Papadakis; Siva Muthusamy; Dianne E Lee; Wael G Ibrahim; Anand Nair; Deloris Koziol; Dragan Maric; Dima A Hammoud
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

View more
  31 in total

1.  Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure.

Authors:  Adam R Denton; Srimal A Samaranayake; Kristin N Kirchner; Robert F Roscoe; Shane N Berger; Steven B Harrod; Charles F Mactutus; Parastoo Hashemi; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

2.  Male HIV-1 transgenic rats show reduced cocaine-maintained lever-pressing compared to F344 wildtype rats despite similar baseline locomotion.

Authors:  Y Wendy Huynh; Brady M Thompson; Christopher E Larsen; Shilpa Buch; Ming-Lei Guo; Rick A Bevins; Jennifer E Murray
Journal:  J Exp Anal Behav       Date:  2020-02-20       Impact factor: 2.468

3.  Optimizing animal models for HIV-associated CNS dysfunction and CNS reservoir research.

Authors:  Jeymohan Joseph
Journal:  J Neurovirol       Date:  2018-03-26       Impact factor: 2.643

4.  Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.

Authors:  David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry
Journal:  Neurotox Res       Date:  2019-07-08       Impact factor: 3.911

Review 5.  An Empirical Mediation Analysis of Mechanisms Underlying HIV-1-Associated Neurocognitive Disorders.

Authors:  Kristen A McLaurin; Charles F Mactutus; Rosemarie M Booze; Amanda J Fairchild
Journal:  Brain Res       Date:  2019-09-09       Impact factor: 3.252

6.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

7.  The Power of Interstimulus Interval for the Assessment of Temporal Processing in Rodents.

Authors:  Kristen A McLaurin; Landhing M Moran; Hailong Li; Rosemarie M Booze; Charles F Mactutus
Journal:  J Vis Exp       Date:  2019-04-19       Impact factor: 1.355

8.  Dose-dependent neurocognitive deficits following postnatal day 10 HIV-1 viral protein exposure: Relationship to hippocampal anatomy parameters.

Authors:  Sylvia Fitting; Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2017-10-27       Impact factor: 2.457

9.  Glycogen synthase kinase-3 inhibition rescues sex-dependent contextual fear memory deficit in human immunodeficiency virus-1 transgenic mice.

Authors:  Shamsudheen Moidunny; Michael A Benneyworth; David J Titus; Eleonore Beurel; Udhghatri Kolli; Joyce Meints; Richa Jalodia; Sundaram Ramakrishnan; Coleen M Atkins; Sabita Roy
Journal:  Br J Pharmacol       Date:  2020-11-23       Impact factor: 8.739

10.  S-EQUOL: a neuroprotective therapeutic for chronic neurocognitive impairments in pediatric HIV.

Authors:  Kristen A McLaurin; Hailong Li; Anna K Cook; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2020-09-01       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.